PURPOSE: The aims of this study are to evaluate the sensitivity of FDG PET/CT for detection of soft tissue and osseous sarcomas on the basis of FDG avidity. METHODS: We retrospectively evaluated 212 consecutive patients with known soft tissue or osseous sarcoma who had undergone a FDG PET/CT study for the initial staging or assessment of recurrence of disease. The maximum standardized uptake value (SUVmax) of each primary and/or most intense metastatic lesion was measured and compared with the histological data provided in the final pathological reports. An SUVmax of 2.5 or greater was considered positive for our analysis. RESULTS: Sufficient histopathological data were available for 160 soft tissue sarcomas and 52 osseous sarcomas. FDG PET/CT detected 93.9% of all sarcomas with a sensitivity of 93.7% for soft tissue sarcomas and 94.6% for osseous sarcomas. The sensitivities of the most common sarcoma histologies were 100% for leiomyosarcomas, 94.7% for osteosarcomas, 100% for Ewing's sarcomas, 88.9% for liposarcomas, 80.0% for synovial sarcomas, 100% for gastrointestinal stromal tumors, 87.5% for malignant peripheral nerve sheath tumors, 100% for fibroblastic and myoblastic sarcomas, and 100% for malignant fibrohistiocytic tumors. The receiver-operating characteristic curve revealed an area under the curve of 94% for the discrimination of low-grade and high-grade sarcomas imaged for initial staging by FDG PET/CT. CONCLUSION: The combined metabolic and morphological information of FDG PET/CT imaging allows high sensitivity for the detection of various sarcomas and accurate discrimination between newly diagnosed low-grade and high-grade sarcomas.
PURPOSE: The aims of this study are to evaluate the sensitivity of FDG PET/CT for detection of soft tissue and osseous sarcomas on the basis of FDG avidity. METHODS: We retrospectively evaluated 212 consecutive patients with known soft tissue or osseous sarcoma who had undergone a FDG PET/CT study for the initial staging or assessment of recurrence of disease. The maximum standardized uptake value (SUVmax) of each primary and/or most intense metastatic lesion was measured and compared with the histological data provided in the final pathological reports. An SUVmax of 2.5 or greater was considered positive for our analysis. RESULTS: Sufficient histopathological data were available for 160 soft tissue sarcomas and 52 osseous sarcomas. FDG PET/CT detected 93.9% of all sarcomas with a sensitivity of 93.7% for soft tissue sarcomas and 94.6% for osseous sarcomas. The sensitivities of the most common sarcoma histologies were 100% for leiomyosarcomas, 94.7% for osteosarcomas, 100% for Ewing's sarcomas, 88.9% for liposarcomas, 80.0% for synovial sarcomas, 100% for gastrointestinal stromal tumors, 87.5% for malignant peripheral nerve sheath tumors, 100% for fibroblastic and myoblastic sarcomas, and 100% for malignant fibrohistiocytic tumors. The receiver-operating characteristic curve revealed an area under the curve of 94% for the discrimination of low-grade and high-grade sarcomas imaged for initial staging by FDG PET/CT. CONCLUSION: The combined metabolic and morphological information of FDG PET/CT imaging allows high sensitivity for the detection of various sarcomas and accurate discrimination between newly diagnosed low-grade and high-grade sarcomas.
Authors: Matthias H M Schwarzbach; Ulf Hinz; Antonia Dimitrakopoulou-Strauss; Frank Willeke; Servando Cardona; Gunhild Mechtersheimer; Thomas Lehnert; Ludwig G Strauss; Christian Herfarth; Markus W Büchler Journal: Ann Surg Date: 2005-02 Impact factor: 12.969
Authors: M H Schwarzbach; A Dimitrakopoulou-Strauss; F Willeke; U Hinz; L G Strauss; Y M Zhang; G Mechtersheimer; N Attigah; T Lehnert; C Herfarth Journal: Ann Surg Date: 2000-03 Impact factor: 12.969
Authors: M Schulte; D Brecht-Krauss; B Heymer; A Guhlmann; E Hartwig; M R Sarkar; C G Diederichs; A Von Baer; J Kotzerke; S N Reske Journal: J Nucl Med Date: 2000-10 Impact factor: 10.057
Authors: E Bastiaannet; H Groen; P L Jager; D C P Cobben; W T A van der Graaf; W Vaalburg; H J Hoekstra Journal: Cancer Treat Rev Date: 2004-02 Impact factor: 12.111
Authors: Giorgio Treglia; Marco Salsano; Antonella Stefanelli; Maria Vittoria Mattoli; Alessandro Giordano; Lorenzo Bonomo Journal: Skeletal Radiol Date: 2011-11-10 Impact factor: 2.199
Authors: Louie L Gaston; Claudia Di Bella; John Slavin; Rodney J Hicks; Peter F M Choong Journal: Skeletal Radiol Date: 2011-02-06 Impact factor: 2.199
Authors: Lukas M Nystrom; Nickolas B Reimer; Cooper W Dean; Charles H Bush; Mark T Scarborough; C Parker Gibbs Journal: J Bone Joint Surg Am Date: 2015-01-07 Impact factor: 5.284
Authors: Chandala Chitguppi; Ian Koszewski; Kaitlin Collura; Mark Curtis; Gurston Nyquist; Mindy Rabinowitz; Marc Rosen Journal: J Neurol Surg B Skull Base Date: 2018-07-16